Natural products in cancer chemotherapy: Past, present and future

Nature Reviews Cancer

Volumn 2, Issue 2, 2002, Pages 143-148

  Mann, John ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINONE DERIVATIVE; BLEOMYCIN; BRYOSTATIN 1; CISPLATIN; COMBRETASTATIN A4; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ELEUTHEROBIN; EPOTHILONE A; FLUOROURACIL; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMTUZUMAB OZOGAMICIN; IRINOTECAN; LAVENDUSTIN A; MIDOSTAURIN; MITOMYCIN C; NATURAL PRODUCT; PACLITAXEL; RADICICOL; STAUROSPORINE DERIVATIVE; TOPOTECAN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; BIOLOGICAL PRODUCT; PLANT EXTRACT;

ACUTE LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DRUG SYNTHESIS; ESOPHAGUS CANCER; GENE IDENTIFICATION; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; META ANALYSIS; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; STOMACH CANCER; UTERINE CERVIX CANCER; ANIMAL; ARTICLE; DRUG DESIGN; DRUG SCREENING; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; STRUCTURE ACTIVITY RELATION; VASCULARIZATION;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; NEOPLASMS; PLANT EXTRACTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036488643     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc723     Document Type: Review

References (51)

1. Pettit, G. R., Pierson, F. H. & Herald, C. L. Anticancer Drugs from Animals, Plants and Microorganisms (Wiley, New York, 1994).
2. Newman, D. J., Cragg, G. M. & Snader, K. M. The influence of natural products on drug discovery. Nat. Prod. Rep. 17, 215-234 (2000).
3. Zubrod, C. G. Origins and development of chemotherapy research at the National Cancer Institute Cancer Treat. Rep. 68, 9-19 (1984).
4. Cragg, G. M. et al. In Human Medicinal Agents from Plants (eds. Kinghorn, A. D. & Balandrin, M. F.) 80-95 (ACS, Washington, 1993).
5. Fahy, J. Modifications of the Vinca alkaloids have major implications for tubulin interacting activities. Curr. Pharmaceut. Design 7, 1181-1197 (2001).
6. Hande, K. R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer, 34, 1514-1521 (1998).
7. Goodman, J. & Walsh, V. The Story of Taxol (Cambridge Univ. Press, Cambridge, UK, 2001).
8. Gueritte-Voegelein, F. et al. Relationships between the structure of Taxol analogues and their antimitotic activity. J. Med. Chem. 84, 992-998 (1991).
9. Schiff, P. B., Fant, J. & Horwitz, S. Promotion of microtubule assembly in vitro by Taxol. Nature 277, 665-667 (1979).
10. Kingston, D. G. I. Taxol, a molecule for all seasons. Chem. Commun. 867-880 (2001).
11. Chesnoff, S. The use of Taxol as a trademark. Nature 374, 208 (1995).
12. Jonsson, E. et al. Differential activity of topotecan and irinotecan. Eur. J. Cancer 36, 2120-2127 (2000).
13. Chen, A. Y. & Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharm. Toxicol. 34, 191-218 (1994).
14. Leitheiser, C. J., Rishel, M. J. Wu, X. & Hecht, S. M. Solid-phase synthesis of bleomycin group antibiotics Elaboration of deglycobleomycin A (5). Org. Lett. 2, 3397-3399 (2000).
15. Hofle, G. et al. Structure ekucidation of epothilones. Angew. Chemie 35, 1567-1569 (1996).
16. Nicolaou, K. C., Roschangar, F. & Vourloumis, D. Chemical biology of epothilones. Angew. Chemie 37, 2014-2045 (1998).
17. Nicolaou, K. C., Ritzen, A. & Namoto, K. Recent developments in the chemistry, biology and medicine of the epothilones. Chem. Commun. 1523-1535 (2001).
18. Nicolaou, K. C. et al. Designed epothilones: combinatorial synthesis, tubulin assembly properties, and cytotoxic action against Taxol-resistant tumour cells. Angew. Chemie 36, 2097-2100 (1997).
19. Danishefsky, S. J. et al. On the interactivity of complex synthesis and tumor pharmacology in the drug discovery process (epothilone analogues). J. Org. Chem. 66, 4369-4378 (2001).
20. Faulkner, D. J. Highllights of marine natural products chemistry (1972-1999). Nat. Prod. Rep. 17, 1-6 (2000).
21. Faulkner, D. J. Marine natural products. Nat. Prod. Rep. 17, 50-65 (2001).
22. Nuijen, B. et al. Pharmaceutical developments of anticancer agents derived from marine sources. Anti-Cancer Drugs 11, 793-811 (2000).
23. Mendola, D. in Drugs from the Sea (ed. N. Fusetani) 121-133 (Karger, Basel, 2000).
24. Watson, C. Polymer-supported synthesis of non-oligomeric natural products. Angew. Chemie 38, 1903-1908 (1999).
25. Terrett, N. K., Gardner, M., Gordon, D. W., Kobylecki, R. J. & Steele, J. Combinatorial synthesis: the design of compound libraries and their application to drug discovery. Tetrahedron 51, 8135-8173 (1995).
26. Mutter, R. & Wills, M. Chemistry and biology of the bryostatins. Bioorg. Med. Chem. 8, 1841-1860 (2000).
27. Wender, P. A. et al. The design, computer modeling, solution structure, and biological evaluation of synthetic analogues of bryostatin 1. Proc. Natl. Acad. Sci. USA 95, 6624-6629 (1998).
28. Wender, P. A. & Lippa, B. Synthesis and biological evaluation of bryostatin anaologues. Tet. Lett. 41, 1007-1011 (2000).
29. D'Ambrosio, M., Guerriero, A. & Pietra, F. Sarcodictyin. Helv. Chim. Acta 70, 2019 (1987).
30. Fenical, W. et al. Eleutherobin. J. Am. Chem. Soc. 119, 8744-8745 (1997).
31. Nicolaou, K. C. et al. Total synthesis of eleutherobin. Angew. Chemie. 36, 2520-2524 (1997).
32. Danishefsky, S. J. et al. The total synthesis of eleutherobin. Angew. Chemie 37, 185-187, 789-791 (1998).
33. Nicolaou, K. C. et al. Solid and solution phase synthesis and biological evaluation of combinatorial sarcodictyin libraries. J. Am. Chem. Soc. 120, 10814-10826 (1998).
34. Kohler, G. & Milstein, C. Contimous cultures of fused cells secreting antibody of prediefined specificity. Nature 256, 495-497 (1975).
35. Niculescu-Duvaz, I. & Springer, C. J. Antibody-driected enzyme prodrug therapy (ADEPT). Adv. Drug Delivery Rev. 26, 151-172 (1997).
36. Smyth, T. P., O'Donnell, M. E., O'Connor, M. J. & St Ledger, J. O. β-lactamase-dependent prodrugs-recent developments. Tetrahedron 56, 5699-5707 (2000).
37. Bross, P. F. et al. Approval summary: gemtuzumab ozogamicin (Mylotarg) in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496 (2001).
38. Langer, M., Kratz, F., Rothen-Rutishauser, B., Wunderli-Allenspach, H. & Beck-Sickinger, A. G. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem. 44, 1341-1348 (2001).
39. Corey, E. J., Gin, D. Y. & Kania, R. S. Enantioselective total synthesis of exteinascidin 743. J. Am. Chem. Soc. 118, 9202-9203 (1996).
40. Liekens, S., De Clercq, E. & Neyts, J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61, 253-270 (2001).
41. Folkman, J. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557 (1990).
42. Wernert, N. et al. Inhibition of Ets-1 transcription factor expression by the antibiotic fumagillin. Angew. Chemie 38, 3228-3231 (1999).
43. Pettit, G. R. et al. Isolation and structure of the strong cell-growth and tubulin inhibitor combretastatin A4. Experientia 45, 209-211 (1989).
44. Griggs, J., Metcalfe, J. C. & Hesketh, R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol. 2, 82-87 (2001).
45. Grosios, K., Loadman, P. M., Swaine, D. J., Pettit, G. R. & Bibby, M. C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 20, 229-233 (2000).
46. Weinstein-Oppenheimer, C. R., Blalock, W. L., Steelman, L. S., Chang, F. & McCubrey, J. A. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol. Ther. 88, 229-279 (2000).
47. Sano, M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs. Neuropharmacology 40, 947-953 (2001).
48. Cushman, M. et al. Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGRF and Syk tyrosine kinases, as well as tubulin polymerisation J. Med. Chem. 44, 441-452 (2001).
49. Fabbro, D. et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther. 82, 293-301 (1999).
50. Mann, J. et al. A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline. Bioorg. Med. Chem. Lett. 10, 2063-2066 (2000).
51. Autexier, C. Telomerase as a possible target for anticancer therapy. Chem. Biol. 6, 299-303 (1999).